Cargando…
Rifamycin SV-MMX(®) for treatment of travellers’ diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria
BACKGROUND: The novel oral antibiotic formulation Rifamycin SV-MMX(®), with a targeted delivery to the distal small bowel and colon, was superior to placebo in treating travellers’ diarrhea (TD) in a previous study. Thus, a study was designed to compare this poorly absorbed antibiotic with the syste...
Autores principales: | Steffen, Robert, Jiang, Zhi-Dong, Gracias Garcia, Mónica L, Araujo, Prithi, Stiess, Michael, Nacak, Tanju, Greinwald, Roland, DuPont, Herbert L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331114/ https://www.ncbi.nlm.nih.gov/pubmed/30462260 http://dx.doi.org/10.1093/jtm/tay116 |
Ejemplares similares
-
Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers’ diarrhoea: reply
por: Steffen, Robert, et al.
Publicado: (2019) -
Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy
por: DuPont, Herbert L, et al.
Publicado: (2023) -
Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX(®) Modified Release Tablets in Healthy Male and Female Volunteers
por: Di Stefano, Andrea Francesco Daniele, et al.
Publicado: (2021) -
The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea
por: Koo, Hoonmo L, et al.
Publicado: (2009) -
Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)